{"id":"fotemustine-and-ipilimumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fotemustine is an alkylating agent that damages tumor cell DNA, while ipilimumab blocks CTLA-4 on T cells, removing inhibitory signals and enhancing T-cell activation and proliferation against cancer cells. The combination aims to leverage chemotherapy-induced tumor cell death with enhanced immune checkpoint blockade to improve anti-tumor immune responses.","oneSentence":"Fotemustine is a nitrosourea chemotherapy agent combined with ipilimumab, a CTLA-4 inhibitor that enhances anti-tumor immunity by blocking immune checkpoint inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:25.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT02460068","phase":"PHASE3","title":"A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis","status":"UNKNOWN","sponsor":"Italian Network for Tumor Biotherapy Foundation","startDate":"2012-12","conditions":"Brain Metastases","enrollment":168},{"nctId":"NCT01654692","phase":"PHASE2","title":"A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma","status":"COMPLETED","sponsor":"Italian Network for Tumor Biotherapy","startDate":"2010-06","conditions":"Metastatic Malignant Melanoma","enrollment":86}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fotemustine (Muphoran);","Ipilimumab (YERVOY)"],"phase":"phase_3","status":"active","brandName":"Fotemustine and Ipilimumab","genericName":"Fotemustine and Ipilimumab","companyName":"Italian Network for Tumor Biotherapy Foundation","companyId":"italian-network-for-tumor-biotherapy-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fotemustine is a nitrosourea chemotherapy agent combined with ipilimumab, a CTLA-4 inhibitor that enhances anti-tumor immunity by blocking immune checkpoint inhibition. Used for Metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}